SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer

Sponsor
Fujian Cancer Hospital
Study ID
NCT07256236
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Sacituzumab tirumotecan — DRUG
    intravenous (IV) infusion (4mg/kg, Q2W)
  • QL1706 — DRUG
    intravenous (IV) infusion (3mg/kg, Q2W). Continuous administration will be maintained until radiological disease progression, occurrence of intolerable toxicity, the participant requests to discontinue treatment, or other treatment discontinuation criteria specified in the protocol are met (whichever occurs first). The maximum duration of administration for QL1706 is 24 months.

Study Details

This study is a prospective, single arm II clinical trial. The main objective of the study is to evaluate the efficacy and safety of the combination of Sacituzumab Tirumotecan (SKB264) and QL1706 in the treatment of recurrent or metastatic cervical cancer.

Key Dates

First listed
Dec 1, 2025
Start date
Jan 28, 2026
Status verified
Mar 2026
Primary completion
Jun 30, 2028
Completion
Dec 15, 2028

Study Design

Enrollment
89 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: SKB264+QL1706

Primary Outcome Measure

Objective Response Rate (ORR) [ Time Frame: Up to approximately 24 months ]

Central Contacts

Find similar trials

Nationwide
Cervical cancer trialsOncology trialsGynecologic oncology trialsWomen's health trials

Related Studies